Cargando…

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC

As shortened telomeres inhibit tumor formation and prolong life span in a Kras(G12D) mouse lung cancer model, we investigated the implications of telomerase in Kras-mutant NSCLC. We found that Kras mutations increased TERT (telomerase reverse transcriptase) mRNA expression and telomerase activity an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Weiran, Yin, Yuesong, Wang, Jun, Shi, Bowen, Zhang, Lianmin, Qian, Dong, Li, Chenguang, Zhang, Hua, Wang, Shengguang, Zhu, Jinfang, Gao, Liuwei, Zhang, Qiang, Jia, Bin, Hao, Ligang, Wang, Changli, Zhang, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352098/ https://www.ncbi.nlm.nih.gov/pubmed/27329725 http://dx.doi.org/10.18632/oncotarget.10162

Ejemplares similares

Prognostic Value Analysis of Mutational and Clinicopathological Factors in Non-Small Cell Lung Cancer
por: Li, Chenguang, et al.
Publicado: (2014)

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
por: Garrido, Pilar, et al.
Publicado: (2017)

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
por: Nollmann, Friederike Inga, et al.
Publicado: (2020)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

PinX1 Is a Potential Prognostic Factor for Non-Small-Cell Lung Cancer and Inhibits Cell Proliferation and Migration
por: Wang, Shengguang, et al.
Publicado: (2017)

Prognostic Significance of Combination of Preoperative Platelet Count and Neutrophil-Lymphocyte Ratio (COP-NLR) in Patients with Non-Small Cell Lung Cancer: Based on a Large Cohort Study
por: Zhang, Hua, et al.
Publicado: (2015)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis
por: Zhang, Hua, et al.
Publicado: (2016)

Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer
por: Gao, Liuwei, et al.
Publicado: (2017)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models
por: Haley, John A., et al.
Publicado: (2014)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

KRAS in NSCLC: State of the Art and Future Perspectives
por: Cascetta, Priscilla, et al.
Publicado: (2022)

Human Telomerase RNA: Telomerase Component or More?
por: Rubtsova, Maria, et al.
Publicado: (2020)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

TERT Promoter Mutations and Telomerase in Melanoma
por: Guo, Yuchen, et al.
Publicado: (2022)

The Presence of Telomere Fusion in Sporadic Colon Cancer Independently of Disease Stage, TP53/KRAS Mutation Status, Mean Telomere Length, and Telomerase Activity
por: Tanaka, Hiromi, et al.
Publicado: (2014)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
por: Brunelli, Laura, et al.
Publicado: (2016)

Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells
por: Chen, Shu-Chen, et al.
Publicado: (2020)

Molecular characterization of Chlamydomonas reinhardtii telomeres and telomerase mutants
por: Eberhard, Stephan, et al.
Publicado: (2019)

Clinical significance of cripto-1 expression in lung adenocarcinoma
por: Zhang, Hua, et al.
Publicado: (2017)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

The Telomerase Database
por: Podlevsky, Joshua D., et al.
Publicado: (2008)

Transforming with telomerase
por: Van Epps, Heather L.
Publicado: (2006)

Telomerase structure()
por: Sandin, Sara, et al.
Publicado: (2014)

The current landscape of using direct inhibitors to target KRAS(G12C)-mutated NSCLC
por: Batrash, Firas, et al.
Publicado: (2023)

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
por: Xie, Mingying, et al.
Publicado: (2021)

Telomerase reverse transcriptase moonlights: Therapeutic targets beyond telomerase
por: Maida, Yoshiko, et al.
Publicado: (2015)

Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
por: Jafri, Mohammad A., et al.
Publicado: (2016)

Zinc protoporphyrin binding to telomerase complexes and inhibition of telomerase activity
por: Zhu, Zhaowen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k52a06ra0mprgpph5nf9gpse96